One shot to stop rabies? new vaccine trial begins
NCT ID NCT04270838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new rabies vaccine called ChAdOx2 RabG, given as a single shot. It involves 174 healthy adults (18-45 years) and young children (2-6 years) in a country where rabies is common. The goal is to see if the vaccine is safe and triggers a strong immune response, comparing it to the standard multi-dose rabies vaccine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ChAdOx2 RabG (a viral-vector based rabies vaccine)
What this could lead to
If successful, this could lead to a single-dose rabies vaccine that is easier to administer than current multi-dose regimens, especially in remote areas.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 174 participants, so safety and immune response are still being evaluated. The vaccine may not provide long-lasting protection or could have side effects not yet seen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RABIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IHI Clinical Trial Facility
Bagamoyo, Tanzania